AU2020207203A1 - Novel peptides and uses thereof - Google Patents

Novel peptides and uses thereof Download PDF

Info

Publication number
AU2020207203A1
AU2020207203A1 AU2020207203A AU2020207203A AU2020207203A1 AU 2020207203 A1 AU2020207203 A1 AU 2020207203A1 AU 2020207203 A AU2020207203 A AU 2020207203A AU 2020207203 A AU2020207203 A AU 2020207203A AU 2020207203 A1 AU2020207203 A1 AU 2020207203A1
Authority
AU
Australia
Prior art keywords
peptide
amyloid
disease
subject
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020207203A
Other languages
English (en)
Inventor
Nazneen Dewji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cenna Biosciences Inc
Original Assignee
Cenna Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cenna Biosciences Inc filed Critical Cenna Biosciences Inc
Publication of AU2020207203A1 publication Critical patent/AU2020207203A1/en
Priority to AU2026200229A priority Critical patent/AU2026200229A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2020207203A 2019-01-07 2020-01-06 Novel peptides and uses thereof Abandoned AU2020207203A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026200229A AU2026200229A1 (en) 2019-01-07 2026-01-14 Novel peptides and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789114P 2019-01-07 2019-01-07
US62/789,114 2019-01-07
PCT/US2020/012323 WO2020146236A1 (en) 2019-01-07 2020-01-06 Novel peptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026200229A Division AU2026200229A1 (en) 2019-01-07 2026-01-14 Novel peptides and uses thereof

Publications (1)

Publication Number Publication Date
AU2020207203A1 true AU2020207203A1 (en) 2021-08-19

Family

ID=71520880

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020207203A Abandoned AU2020207203A1 (en) 2019-01-07 2020-01-06 Novel peptides and uses thereof
AU2026200229A Pending AU2026200229A1 (en) 2019-01-07 2026-01-14 Novel peptides and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026200229A Pending AU2026200229A1 (en) 2019-01-07 2026-01-14 Novel peptides and uses thereof

Country Status (9)

Country Link
US (1) US20220064214A1 (https=)
EP (1) EP3908307A4 (https=)
JP (2) JP2022516574A (https=)
KR (1) KR20220004618A (https=)
CN (2) CN113853382A (https=)
AU (2) AU2020207203A1 (https=)
CA (1) CA3125552A1 (https=)
IL (1) IL284666A (https=)
WO (1) WO2020146236A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030077740A1 (en) * 2001-03-05 2003-04-24 Schubert David R. Presenilin/Crk binding polypeptides (PCBP) and methods of use thereof
US8129334B2 (en) * 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
JP2013526518A (ja) * 2010-05-13 2013-06-24 ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション Ｍｃｉおよびアルツハイマー病の処置
CN106456799B (zh) * 2014-06-03 2020-05-22 江苏佳瑞生物技术有限公司 肽-药物偶联物

Also Published As

Publication number Publication date
EP3908307A1 (en) 2021-11-17
CA3125552A1 (en) 2020-07-16
JP2022516574A (ja) 2022-02-28
EP3908307A4 (en) 2022-10-12
CN114437173A (zh) 2022-05-06
IL284666A (en) 2021-08-31
CN113853382A (zh) 2021-12-28
JP2025041635A (ja) 2025-03-26
AU2026200229A1 (en) 2026-02-05
US20220064214A1 (en) 2022-03-03
KR20220004618A (ko) 2022-01-11
WO2020146236A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
JP7517997B2 (ja) プログラニュリンを含む融合タンパク質
JP2023507846A (ja) プログラニュリン変異体
JP2006505243A (ja) Ｍｃｐタンパク質の新規のアンタゴニスト
JP2026035742A (ja) 生体高分子標的特異的補体阻害剤及びその製造方法と応用
KR102569658B1 (ko) 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도
Zhong et al. Pyroglutamate and O-linked glycan determine functional production of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions
WO2021133907A1 (en) Progranulin variants
WO2024200988A1 (en) Tnfr2 binding polypeptides and methods of use
JP2009519006A (ja) 改善された色素上皮由来因子変異体及びその使用
US20220064214A1 (en) Novel peptides and uses thereof
US20220034913A1 (en) Methods and compostions of detecting and treating neurodegenerative disorders
CN108864258A (zh) 具有抑制肿瘤功能的peg化多肽及其制备方法与应用
US6893844B1 (en) DNA encoding a new human hepatoma derived growth factor and producing method thereof
WO2014061772A1 (ja) 新規ｎｋ３受容体アゴニスト
KR101829631B1 (ko) 신규 펩타이드 및 그 용도
WO2020154363A1 (en) Engineered nucleobindin1-immunoglobulin fusion protein
HK40084870A (en) Biological macromolecular target-specific complement inhibitor, preparation method therefor, and application thereof
WO2023081825A2 (en) Active immunization against amyloid and aging-related diseases
KR20250089536A (ko) 억제제
WO2015104443A1 (es) Agentes moduladores de n-procalcitonina para la prevención y el tratamiento de enfermedades neurodegenerativas
EA049817B1 (ru) Варианты програнулина
HK40121727A (zh) Serpin肽衍生物及其使用方法
JP2022544401A (ja) Ｔｇｆ－ベータトラップ
Levitzki M1–Peptidomimetics and Signal Transduction Inhibition
Saad et al. Salivary flow, sodium renal excretion, urinary volume and arterial blood pressure induced by pilocarpine: influence of nitric oxide

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted